Dora Steel1, Marion Main1, Adnan Manzur1, Francesco Muntoni1,2, Pinki Munot1. 1. Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Children, London, UK. 2. Great Ormond Street Institute of Child Health, University College London, London, UK.
Abstract
AIM: To explore the clinical course of patients presenting with facioscapulohumeral dystrophy type 1 (FSHD1) in childhood, with a view to identifying areas where they differed from older patients and where extra support or monitoring might be required. METHOD: A retrospective case-notes review of children with FSHD1 seen at a tertiary paediatric neuromuscular centre between 2002 and 2016 was performed. Data collected included age at and nature of presentation, path to diagnosis, genetic testing results, motor function, and occurrence of extramuscular features and complications. RESULTS: Eighteen children (11 females, seven males; mean [SD] age at latest review 13y 10mo [3y 9mo], range 8-19y) from 16 families were identified. Age at onset of FSHD1 correlated with the size of deletion (r=0.81) and most presentations were in children either younger than 5 years or older than 10 years. Children with onset before 5 years were more likely to present with non-muscular symptoms and to develop extramuscular pathology, including developmental and psychiatric issues, hearing or visual impairments, and problems involving respiratory function and nutrition. No cases of epilepsy or cardiac arrhythmia were identified but two children died. INTERPRETATION: The complexity and severity of FSHD1 presenting in early childhood underlines the importance of a multidisciplinary approach to the disorder. WHAT THIS PAPER ADDS: Young children often present with non-muscular pathology in facioscapulohumeral dystrophy type 1 (FSHD1), especially hearing loss. Age at onset in paediatric FSHD1 appears bimodal: under 5 years or in adolescence. Prolonged delays to diagnosis are common. Children with very early-onset FSHD1 may require nutritional and/or respiratory support. Developmental and psychiatric comorbidities are common.
AIM: To explore the clinical course of patients presenting with facioscapulohumeral dystrophy type 1 (FSHD1) in childhood, with a view to identifying areas where they differed from older patients and where extra support or monitoring might be required. METHOD: A retrospective case-notes review of children with FSHD1 seen at a tertiary paediatric neuromuscular centre between 2002 and 2016 was performed. Data collected included age at and nature of presentation, path to diagnosis, genetic testing results, motor function, and occurrence of extramuscular features and complications. RESULTS: Eighteen children (11 females, seven males; mean [SD] age at latest review 13y 10mo [3y 9mo], range 8-19y) from 16 families were identified. Age at onset of FSHD1 correlated with the size of deletion (r=0.81) and most presentations were in children either younger than 5 years or older than 10 years. Children with onset before 5 years were more likely to present with non-muscular symptoms and to develop extramuscular pathology, including developmental and psychiatric issues, hearing or visual impairments, and problems involving respiratory function and nutrition. No cases of epilepsy or cardiac arrhythmia were identified but two children died. INTERPRETATION: The complexity and severity of FSHD1 presenting in early childhood underlines the importance of a multidisciplinary approach to the disorder. WHAT THIS PAPER ADDS: Young children often present with non-muscular pathology in facioscapulohumeral dystrophy type 1 (FSHD1), especially hearing loss. Age at onset in paediatric FSHD1 appears bimodal: under 5 years or in adolescence. Prolonged delays to diagnosis are common. Children with very early-onset FSHD1 may require nutritional and/or respiratory support. Developmental and psychiatric comorbidities are common.
Authors: Darko Bosnakovski; Ahmed S Shams; Ce Yuan; Meiricris T da Silva; Elizabeth T Ener; Cory W Baumann; Angus J Lindsay; Mayank Verma; Atsushi Asakura; Dawn A Lowe; Michael Kyba Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Jildou N Dijkstra; Rianne J M Goselink; Nens van Alfen; Imelda J M de Groot; Maaike Pelsma; Nienke van der Stoep; Thomas Theelen; Baziel G M van Engelen; Nicol C Voermans; Corrie E Erasmus Journal: Neurology Date: 2021-10-21 Impact factor: 9.910
Authors: Andrea C Kakouri; Demetris Koutalianos; Andrie Koutsoulidou; Anastasis Oulas; Marios Tomazou; Nikoletta Nikolenko; Chris Turner; Andreas Roos; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; Eleni Zamba Papanicolaou; Grainne Gorman; Hanns Lochmüller; George M Spyrou; Leonidas A Phylactou Journal: RNA Biol Date: 2021-12-31 Impact factor: 4.652